Similar articles

• Adrenal and pituitary effects of mitotane in Cushing's syndrome.

  Kasperlik-Załuska A, Jeske W, Migdalska B. Kasperlik-Załuska A, et al. Endokrynol Pol. 1986;37(1):17-21. Endokrynol Pol. 1986. PMID: 3015579 No abstract available.
• [The medical management of Cushing's syndrome].

  Leal-Cerro A, Soto Moreno A, Mangas MA, León Justel A, Webb S. Leal-Cerro A, et al. Endocrinol Nutr. 2009 Apr;56(4):187-94. doi: 10.1016/S1575-0922(09)70983-0. Epub 2009 Jun 11. Endocrinol Nutr. 2009. PMID: 19627735 Review. Spanish.
• [Results of treatment of Cushing's syndrome with chloditane and large doses of reserpine].

  Komissarenko IV, Cheban AK, Rybakov SI, Pomerantsev IuV. Komissarenko IV, et al. Probl Endokrinol (Mosk). 1983 Sep-Oct;29(5):15-8. Probl Endokrinol (Mosk). 1983. PMID: 6316321 Russian.
• Cushing's syndrome.

  Krieger DT. Krieger DT. Monogr Endocrinol. 1982;22:1-142. Monogr Endocrinol. 1982. PMID: 6278296 Review. No abstract available.
• [Changes in functional state of the thyroid gland and thyrotropic activity of the pituitary gland in Cushing's syndrome after unilateral adrenalectomy combined with radiation therapy].

  Kalinin AP, Bogatyrev OP, Tishenina RS, Khzardzhian VG, Naryzhniuk ND. Kalinin AP, et al. Ter Arkh. 1978;50(11):75-80. Ter Arkh. 1978. PMID: 214891 Russian. No abstract available.